Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 3
2020 7
2021 8
2022 4
2023 7
2024 4
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Iron Chelation Therapy.
Cappellini MD, Scaramellini N, Leoni S, Motta I. Cappellini MD, et al. Among authors: scaramellini n. Adv Exp Med Biol. 2025;1480:361-370. doi: 10.1007/978-3-031-92033-2_23. Adv Exp Med Biol. 2025. PMID: 40603802 Review.
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Taher AT, Al-Samkari H, Aydinok Y, Besser M, Boscoe AN, Dahlin JL, De Luna G, Estepp JH, Gheuens S, Gilroy KS, Glenthøj A, Sim Goh A, Iyer V, Kattamis A, Loggetto SR, Morris S, Musallam KM, Osman K, Ricchi P, Salido-Fiérrez E, Sheth S, Tai F, Tevich H, Uhlig K, Urbstonaitis R, Viprakasit V, Cappellini MD, Kuo KHM; ENERGIZE investigators. Taher AT, et al. Lancet. 2025 Jul 5;406(10498):33-42. doi: 10.1016/S0140-6736(25)00635-X. Epub 2025 Jun 19. Lancet. 2025. PMID: 40544857 Clinical Trial.
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients.
Cicco S, D Abbondanza M, Proietti M, Zaccone V, Pes C, Caradio F, Mattioli M, Piano S, Marra AM, Nobili A, Mannucci PM, Pietrangelo A, Sesti G, Buzzetti E, Salzano A, Cimellaro A; Giovani Internisti Società Italiana di Medicina Interna (GIS-SIMI) and of the REPOSI Investigators. Cicco S, et al. Eur J Clin Invest. 2023 Apr;53(4):e13931. doi: 10.1111/eci.13931. Epub 2022 Dec 21. Eur J Clin Invest. 2023. PMID: 36453932 Free article.
Splenomegaly: Dare to think rare.
Scaramellini N, Croci G, De Magistris C, Panzieri DL, Cassinerio E, Marcon A, Nascimbeni F, Quarta A, Cappellini MD, Motta I. Scaramellini N, et al. Am J Hematol. 2022 Sep;97(9):1259-1265. doi: 10.1002/ajh.26559. Epub 2022 Apr 22. Am J Hematol. 2022. PMID: 35384034 Free article. No abstract available.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion-dependent β-thalassemia.
Panzieri DL, Consonni D, Scaramellini N, Ausenda G, Granata F, Caponio N, Duca L, Leoni S, Elli S, Ferraresi M, Bolis V, Curcio C, Irrera MA, Maira D, Graziadei G, Cassinerio E, Cappellini MD, Bou-Fakhredin R, Brancaleoni V, Motta I. Panzieri DL, et al. Among authors: scaramellini n. Am J Hematol. 2024 Dec;99(12):2395-2398. doi: 10.1002/ajh.27474. Epub 2024 Sep 12. Am J Hematol. 2024. PMID: 39264036 Free article. No abstract available.
Gene therapy for sickle cell disease and thalassemia.
Scaramellini N, Panzieri DL, Cappellini MD. Scaramellini N, et al. Curr Opin Hematol. 2025 May 1;32(3):120-129. doi: 10.1097/MOH.0000000000000867. Epub 2025 Feb 27. Curr Opin Hematol. 2025. PMID: 40013946 Review.
Understanding and targeting erythroid cell metabolism.
Ni M, Scaramellini N, Motta I, Xu J. Ni M, et al. Among authors: scaramellini n. Trends Cell Biol. 2025 Nov 3:S0962-8924(25)00224-7. doi: 10.1016/j.tcb.2025.10.001. Online ahead of print. Trends Cell Biol. 2025. PMID: 41184165 Review.
35 results